Tumor necrosis factor (TNF), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β) (TNF, IL-6, IL-1β)

Pro-inflammatory cytokines, specifically Tumor Necrosis Factor (TNF), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β), are key signaling proteins that mediate and amplify the inflammatory response (StatPearls, 2023). Produced primarily by activated macrophages, monocytes, and T-lymphocytes, these molecules regulate immune cell recruitment, vascular permeability, and the acute-phase response (NCBI, 2022). While essential for host defense against pathogens, their dysregulation or chronic overproduction is a hallmark of numerous autoimmune and autoinflammatory disorders, including rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus (PubMed, 2021). These cytokines often act in a cascade, where TNF and IL-1β can induce the production of IL-6, leading to systemic effects like fever and the production of acute-phase proteins by the liver (NCBI, 2023). Pharmacological intervention typically involves monoclonal antibodies or decoy receptors that sequester the cytokines or block their cognate receptors, thereby dampening the inflammatory cascade (Nature Reviews Drug Discovery, 2020). For example, TNF inhibitors like adalimumab and IL-6 inhibitors like tocilizumab have revolutionized the treatment of chronic inflammatory diseases (FDA, 2023). However, because these cytokines are vital for immune surveillance, their inhibition carries significant risks, most notably an increased susceptibility to serious bacterial, viral, and fungal infections (FDA, 2023). Additionally, long-term suppression of these pathways requires careful monitoring for potential side effects such as malignancy or the reactivation of latent infections like tuberculosis (PubMed, 2022).

Other names

Pro-inflammatory cytokinesInflammatory cytokinesPyrogenic cytokinesCytokine storm mediatorsInflammatory mediators

Neutralization of soluble and membrane-bound cytokines or competitive inhibition of their respective cell-surface receptors to prevent downstream intracellular signaling cascades (e.g., NF-κB or JAK-STAT pathways) (StatPearls, 2023; PubMed, 2021).